To describe a case of recurrent, bilateral panuveitis caused by the BRAF proto-oncogene inhibitor vemurafenib.
Methods
Case report.
Results
A 25-year-old woman developed bilateral panuveitis and macular edema after initiating treatment with the BRAF enzyme inhibitor vemurafenib for stage IV cutaneous melanoma. The patient was successfully treated with sub-Tenon triamcinolone injections along with cessation of the medication.
Conclusions
Panuveitis is a potential adverse effect of vemurafenib. Good communication with oncology is necessary, in case the medication needs to be discontinued.
FlahertyK.T., PuzanovI., KimK.B.Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med2010; 363: 809–19.
3.
ChapmanP.B., HauschildA., RobertC.BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med2011; 364: 2507–16.
4.
FraunfelderF.W., RosenbaumJ.T.Drug-induced uveitis. Incidence, prevention and treatment. Drug Saf1997; 17: 197–207.
ZimmerL., LivingstoneE., HillenU., DömkesS., BeckerA., SchadendorfD.Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol2012; 148: 357–61.
